Vizimpro for Non-Small Cell Lung Cancer – Details - Dacomitinib (Vizimpro) NSCLC – Final Clinical Guidance Report
Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.